QTI is a contract analytical research and development laboratory that has been serving the pharmaceutical, medical device and drug delivery industry in North America for over 15 years
Intertek, a provider of quality and safety services to a wide range of industries, has acquired Quantitative Technologies (QTI).
QTI will operate in the Intertek OCA Division (Caleb Brett) pharmaceutical services group.
QTI is located in Whitehouse, New Jersey with approximately 60 staff and counts major global pharmaceutical companies among its clients.
The laboratory is highly regarded for technical expertise, rigorous compliance programmes, and outstanding customer service - it is a current good manufacturing practice (cGMP) facility in good standing with the US Food and Drug Administration (FDA).
The acquisition further advances Intertek's strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry through the provision of state of the art analytical services.
CEO of Intertek's OCA division (Caleb Brett), Mark Loughead, comments: "QTI has an outstanding reputation in the industry and will further expand our ability to support the pharmaceutical and related sectors for outsourced R+D and testing expertise".
John Conti-Ramsden, global director for Intertek Pharmaceutical Services, said: "The acquisition of QTI further develops Intertek's USA offering and global platform in the area of pharmaceutical services.
"Intertek already provides a wide range of testing services to pharmaceutical clients from its laboratories in Europe and good laboratory practice (GLP) bio-analytical services from the Alta laboratories in California".
Paul Winslow, managing director of QTI comments: "Joining Intertek provides QTI a global network to access and serve the worldwide pharmaceutical industry.
"Additionally, Intertek's commitment to growth will allow QTI to expand our capabilities to provide a more comprehensive service offering to our key industry markets."
